705-Targeting Amyloid-β Pathology with CAR-Astrocyte Therapy
Researchers have developed a novel neuroimmunotherapy for Alzheimer’s disease by engineering astrocytes to express chimeric antigen receptors (CARs). While traditional treatments rely on antibodies that often require high doses and repeated administration, this CAR-A therapy enables a one-time, noninvasive delivery to transform brain cells into "super-phagocytes." These specialized cells are designed to specifically target and clear amyloid-β aggregates, which are primary drivers of neurodegeneration. In mouse models, a single treatment significantly reduced existing plaque burden and…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.